Avalo Therapeutics, Inc. 8K

Avalo Therapeutics reported Q2 2026 results, expanded its IL‑1β pipeline, outlined a 2027 Phase 3 start for abdakibart in hidradenitis suppurativa, and noted a cash runway into 2029 alongside a new board appointment and Russell index inclusion.

On August 6, 2026, Avalo Therapeutics, Inc. reported its second quarter 2026 financial results and provided business updates, highlighting plans to initiate a registrational Phase 3 program for its lead IL‑1β antibody abdakibart in hidradenitis suppurativa in the first half of 2027, advancement of its pipeline with the long-acting anti‑IL‑1β candidate AVTX‑010 with an IND filing also targeted for the first half of 2027, the appointment of Ron Philip to the Board of Directors, recent inclusion in the Russell 2000 and 3000 Indexes, and a strengthened balance sheet with $472.2 million in cash, cash equivalents and investments as of June 30, 2026 expected to fund operations into 2029 despite a higher quarterly net loss driven by increased R&D and G&A expenses.

Filing Facts

CIK

1534120

Ticker

-

Form

8K

Source Type

sec

Accession

0001534120-26-000048

Alert Tier

6